These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26364406)

  • 21. Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management.
    Salomone F; Zelber-Sagi S; Galvano F; Fabbrini E
    Biomed Res Int; 2015; 2015():153276. PubMed ID: 26290862
    [No Abstract]   [Full Text] [Related]  

  • 22. NASH, from diagnosis to treatment: Where do we stand?
    Harrison SA
    Hepatology; 2015 Dec; 62(6):1652-5. PubMed ID: 26446314
    [No Abstract]   [Full Text] [Related]  

  • 23. Which patients with nonalcoholic fatty liver disease should undergo liver biopsy?
    Lindenmeyer CC; McCullough AJ
    Cleve Clin J Med; 2017 Apr; 84(4):273-275. PubMed ID: 28388384
    [No Abstract]   [Full Text] [Related]  

  • 24. Leptin in nonalcoholic fatty liver disease: a narrative review.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2015 Jan; 64(1):60-78. PubMed ID: 25456097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of non-alcoholic fatty liver disease.
    Dyson J; Day C
    Dig Dis; 2014; 32(5):597-604. PubMed ID: 25034293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
    Chalasani N; Younossi Z; Lavine JE; Charlton M; Cusi K; Rinella M; Harrison SA; Brunt EM; Sanyal AJ
    Hepatology; 2018 Jan; 67(1):328-357. PubMed ID: 28714183
    [No Abstract]   [Full Text] [Related]  

  • 27. CKD and nonalcoholic fatty liver disease.
    Targher G; Chonchol MB; Byrne CD
    Am J Kidney Dis; 2014 Oct; 64(4):638-52. PubMed ID: 25085644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current Status and Future Prospects of Nonalcoholic Fatty Liver Disease (NAFLD) in Japan-Feedback from Clinical and Basic Researches to Medical Therapy and Pharmacist Activities].
    Tokuyama S; Kim KI
    Yakugaku Zasshi; 2016; 136(4):563. PubMed ID: 27040339
    [No Abstract]   [Full Text] [Related]  

  • 29. Current solutions for obesity-related liver disorders: non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Raziel A; Sakran N; Szold A; Goitein D
    Isr Med Assoc J; 2015 Apr; 17(4):234-8. PubMed ID: 26040050
    [No Abstract]   [Full Text] [Related]  

  • 30. Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease.
    Sanyal AJ; Mathurin P; Nagy LA
    Gastroenterology; 2016 Jun; 150(8):1695-7. PubMed ID: 27155520
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of fatty liver disease with the metabolic syndrome.
    Machado MV; Cortez-Pinto H
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):487-500. PubMed ID: 24665862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of NASH with human mesenchymal stem cells in the immunodeficient mouse.
    Winkler S; Christ B
    Methods Mol Biol; 2014; 1213():51-6. PubMed ID: 25173373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.
    Eng K; Lopez R; Liccardo D; Nobili V; Alkhouri N
    Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis and treatment of non-alcoholic fatty liver disease].
    Su W; Cao H; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Sep; 22(9):705-7. PubMed ID: 25647847
    [No Abstract]   [Full Text] [Related]  

  • 36. [Nonalcoholic fatty liver disease: What do we know and what will we have to learn?].
    Volkova NI; Porksheyan MI
    Ter Arkh; 2017; 89(2):91-98. PubMed ID: 28393828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Strengthen researches on risk factors and early diagnosis of nonalcoholic fatty liver].
    Li YM
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):805-7. PubMed ID: 24516924
    [No Abstract]   [Full Text] [Related]  

  • 38. Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic.
    Bernstein DE
    Clin Liver Dis; 2018 Feb; 22(1):xiii-xiv. PubMed ID: 29128064
    [No Abstract]   [Full Text] [Related]  

  • 39. Paediatric non-alcoholic fatty liver disease: a practical overview for non-specialists.
    Mann JP; Goonetilleke R; McKiernan P
    Arch Dis Child; 2015 Jul; 100(7):673-7. PubMed ID: 25633064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Periostin on the road to nonalcoholic fatty liver disease.
    Polyzos SA; Anastasilakis AD
    Endocrine; 2016 Jan; 51(1):4-6. PubMed ID: 26585566
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.